Novavax, Inc. (NVAX) Earnings History
Annual and quarterly earnings data from 1996 to 2025
Loading earnings history...
NVAX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
NVAX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 93.7% | 50.1% | 39.2% |
| 2024 | 70.3% | -36.5% | -27.5% |
| 2023 | 38.2% | -101.8% | -98.0% |
| 2022 | 43.5% | -40.3% | -41.1% |
| 2021 | 100.0% | -853.6% | -882.5% |
Download Data
Export NVAX earnings history in CSV or JSON format
Free sign-in required to download data
Novavax, Inc. (NVAX) Earnings Overview
As of May 7, 2026, Novavax, Inc. (NVAX) reported trailing twelve-month net income of -$88M, reflecting +306.5% year-over-year growth. The company earned $-0.54 per diluted share over the past four quarters, with a net profit margin of 39.2%.
Looking at the long-term picture, NVAX's historical earnings data spans multiple years. The company achieved its highest annual net income of $440M in fiscal 2025, representing a new all-time high.
Novavax, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including MRNA (-$3.19B net income, -145.2% margin), BNTX (-$1.13B net income, -39.6% margin), PFE ($7.49B net income, 12.4% margin), NVAX has outperformed on profitability metrics. Compare NVAX vs MRNA →
NVAX Earnings vs Peers
Earnings metrics vs comparable public companies
NVAX Historical Earnings Data (1996–2025)
30 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $440M | +334.8% | $563M | $2.54 | 39.2% | 50.1% |
| 2024 | -$187M | +65.6% | -$249M | $-1.23 | -27.5% | -36.5% |
| 2023 | -$545M | +17.2% | -$567M | $-5.41 | -98.0% | -101.8% |
| 2022 | -$658M | +62.3% | -$645M | $-8.42 | -41.1% | -40.3% |
| 2021 | -$1.74B | -316.9% | -$1.69B | $-23.44 | -882.5% | -853.6% |
| 2020 | -$418M | -221.5% | -$417M | $-7.43 | -1868.2% | -1861.3% |
| 2019 | -$130M | +29.6% | -$121M | $-5.40 | -697.1% | -646.1% |
| 2018 | -$185M | -0.5% | -$174M | $-9.99 | -538.8% | -507.2% |
| 2017 | -$184M | +34.4% | -$172M | $-12.56 | -589.5% | -550.8% |
| 2016 | -$280M | -78.4% | -$269M | $-20.68 | -1823.5% | -1752.8% |
See NVAX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NVAX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NVAX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNVAX — Frequently Asked Questions
Quick answers to the most common questions about buying NVAX stock.
Is NVAX growing earnings?
NVAX EPS is $-0.54, with earnings growth accelerating to +306.5%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-88M.
What are NVAX's profit margins?
Novavax, Inc. net margin is +39.2%, with operating margin at +50.1%. Above-average margins indicate pricing power.
How consistent are NVAX's earnings?
NVAX earnings data spans 1996-2025. The accelerating earnings trend is +306.5% YoY. Historical data enables comparison across business cycles.